|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-3-28
|
|
pubmed:abstractText |
The objective of this study was to test the activity and toxicity of epirubicin plus docetaxel as primary chemotherapy for women with large, operable (T2; > 3 cm) or locally advanced (Stage III) breast carcinoma, including patients with inflammatory breast carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 American Cancer Society.DOI 10.1002/cncr.20335
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
895-901
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11920456-Adult,
pubmed-meshheading:11920456-Aged,
pubmed-meshheading:11920456-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11920456-Breast Neoplasms,
pubmed-meshheading:11920456-Epirubicin,
pubmed-meshheading:11920456-Female,
pubmed-meshheading:11920456-Humans,
pubmed-meshheading:11920456-Infusions, Intravenous,
pubmed-meshheading:11920456-Injections, Intravenous,
pubmed-meshheading:11920456-Middle Aged,
pubmed-meshheading:11920456-Neoadjuvant Therapy,
pubmed-meshheading:11920456-Neutropenia,
pubmed-meshheading:11920456-Paclitaxel,
pubmed-meshheading:11920456-Taxoids,
pubmed-meshheading:11920456-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
|
|
pubmed:affiliation |
Department of Medical Oncology C, National Cancer Institute, Naples, Italy. f.conuzzo@libero.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
